心脏手术中急性等容性血液稀释的随机试验
这项多国、单盲随机试验纳入32个中心、11个国家的2010例接受体外循环心脏手术的成人,随机分为急性等容性血液稀释(ANH)组1010例和常规治疗组1000例。ANH组在体外循环开始前采集≥650 ml全血,必要时以晶体液替代,体外循环脱机后回输。主要终点住院期间至少输注1单位异体红细胞:ANH组27.3%(274/1005)vs 常规组29.2%(291/997),RR 0.93(95%CI 0.81–1.07),P=0.34,差异未达统计学显著。术后出血再手术、30天或住院期间死亡及安全结局两组相似。
要点
- 成人体外循环心脏手术中,ANH未减少住院期间异体红细胞输注:27.3%(274/1005)vs 29.2%(291/997),RR 0.93(95%CI 0.81–1.07),P=0.34。
- ANH方案为体外循环开始前采集≥650 ml全血,必要时以晶体液替代,体外循环脱机后回输。
- 术后因出血再手术:ANH组3.8%(38/1004)vs 常规组2.6%(26/995)。
- 30天内或住院期间死亡:ANH组1.4%(14/1008)vs 常规组1.6%(16/997)。
- 安全结局两组相似。
适用人群与场景
- 接受体外循环心脏手术的成人,来自32个中心、11个国家。
处置流程与药物剂量
- ANH组:体外循环开始前采集≥650 ml全血,必要时以晶体液替代,体外循环脱机后回输;对照组接受常规治疗。
研究设计与关键结果
- 多国、单盲随机试验,2010例接受体外循环心脏手术的成人随机分为ANH组1010例和常规治疗组1000例。
- 主要终点住院期间至少输注1单位异体红细胞:ANH组27.3%(274/1005)vs 常规组29.2%(291/997),RR 0.93(95%CI 0.81–1.07),P=0.34。
- 术后出血再手术:ANH组3.8%(38/1004)vs 常规组2.6%(26/995)。
- 30天内或住院期间死亡:ANH组1.4%(14/1008)vs 常规组1.6%(16/997)。
- 安全结局两组相似。
证据类型、等级与局限
- 证据类型:多国、单盲随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在接受心脏手术的成人中,ANH未减少接受异体红细胞输注的患者数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients undergoing cardiac surgery often receive red-cell transfusions, along with the associated risks and costs. Early intraoperative normovolemic hemodilution (i.e., acute normovolemic hemodilution [ANH]) is a blood-conservation technique that entails autologous blood collection before initiation of cardiopulmonary bypass and reinfusion of the collected blood after bypass weaning. More data are needed on whether ANH reduces the number of patients receiving allogeneic red-cell transfusion.
METHODS: In a multinational, single-blind trial, we randomly assigned adults from 32 centers and 11 countries who were undergoing cardiac surgery with cardiopulmonary bypass to receive ANH (withdrawal of ≥650 ml of whole blood with crystalloids replacement if needed) or usual care. The primary outcome was the transfusion of at least one unit of allogeneic red cells during the hospital stay. Secondary outcomes were death from any cause within 30 days after surgery or during the hospitalization for surgery, bleeding complications, ischemic complications, and acute kidney injury.
RESULTS: A total of 2010 patients underwent randomization; 1010 were assigned to ANH and 1000 to usual care. Among patients with available data, 274 of 1005 (27.3%) in the ANH group and 291 of 997 (29.2%) in the usual-care group received at least one allogeneic red-cell transfusion (relative risk, 0.93; 95% confidence interval, 0.81 to 1.07; P = 0.34). Surgery for postoperative bleeding was performed in 38 of 1004 patients (3.8%) in the ANH group and 26 of 995 patients (2.6%) in the usual-care group. Death within 30 days or during hospitalization occurred in 14 of 1008 patients (1.4%) in the ANH group and 16 of 997 patients (1.6%) in the usual-care group. Safety outcomes were similar in the two groups.
CONCLUSIONS: Among adults undergoing cardiac surgery, ANH did not reduce the number of patients receiving allogeneic red-cell transfusion. (Funded by the Italian Ministry of Health; ANH ClinicalTrials.gov number, NCT03913481.).
参考来源
- Monaco F, Lei C, Bonizzoni MA, et al. A Randomized Trial of Acute Normovolemic Hemodilution in Cardiac Surgery. N Engl J Med. 2025. PMID: 40503713. doi:10.1056/NEJMoa2504948
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。